Can I Take Vitamin B6 with Dayvigo (Lemborexant)?

What Is Dayvigo and How Does It Work?

Lemborexant, sold under the brand name Dayvigo, is a dual orexin receptor antagonist (DORA) that blocks both OX1R and OX2R receptors in the brain. Blocking these receptors suppresses the wake-promoting orexin (hypocretin) signal, allowing natural sleep onset rather than inducing broad sedation the way older hypnotics do. The FDA approved lemborexant in December 2019 for adults with insomnia disorder. [1]

Pharmacokinetics Relevant to Drug Interactions

Understanding how lemborexant is metabolized matters for evaluating any co-administered substance. Lemborexant is primarily metabolized by CYP3A4, with minor contributions from CYP3A5. [2] Its plasma half-life is approximately 17 to 19 hours, meaning it remains pharmacologically active well into the following day.

The prescribing information published by Eisai explicitly warns against use with strong or moderate CYP3A4 inhibitors (such as ketoconazole or fluconazole) and against use with strong CYP3A4 inducers (such as rifampin). [2] These interactions can raise or lower lemborexant plasma concentrations to clinically dangerous levels.

Why CYP3A4 Matters for This Conversation

Vitamin B6 is not a recognized CYP3A4 inhibitor or inducer at physiologically relevant concentrations. Studies on pyridoxine and cytochrome P450 enzymes have not identified a meaningful modulatory effect at doses below 200 mg per day. This is why the direct pharmacokinetic risk of combining standard B6 with Dayvigo is considered low by clinical pharmacologists.

What Is Vitamin B6 and Why Do People Take It?

Vitamin B6 refers to a group of six chemically related compounds, the most common supplemental form being pyridoxine hydrochloride. Adults need just 1.3 to 1.7 mg per day from food sources. Supplemental B6 is sold in doses ranging from 2 mg (in most multivitamins) all the way up to 500 mg single-dose tablets. [3]

Common Reasons for B6 Supplementation

People take B6 supplements for a variety of reasons.

• Pregnancy-related nausea (often prescribed as 10 to 25 mg three times daily, the same dose used in Diclegis/Bonjesta combined with doxylamine) [4]
• Premenstrual syndrome symptom management
• Pyridoxine-responsive homocystinuria or sideroblastic anemia
• Adjunct support during isoniazid therapy for tuberculosis (isoniazid depletes B6 by forming hydrazones with pyridoxal phosphate)
• General wellness or "hormone balance" marketing claims with limited evidence

The insomnia connection people sometimes cite is indirect. B6 is a cofactor in serotonin and melatonin synthesis pathways. One small study of 12 participants suggested that high-dose B6 (240 mg) affected dream vividness, though this has not translated into recognized clinical guidance for insomnia treatment. [5]

B6 Toxicity Is Real at High Doses

Sensory peripheral neuropathy from excess pyridoxine is well-documented. The European Food Safety Authority set a tolerable upper intake level of 12.5 mg per day in 2023, lower than the older NIH tolerable upper level of 100 mg per day. [3, 6] Chronic daily intake above 200 mg has been associated with irreversible nerve damage in case series, and some cases have been reported at intakes as low as 50 mg per day sustained over months. [7] This ceiling on B6 safety is independent of any co-medication.

Does Vitamin B6 Interact with Dayvigo Pharmacokinetically?

The short answer: no clinically documented pharmacokinetic interaction exists between vitamin B6 and lemborexant at standard supplemental doses.

CYP3A4 Profile of Vitamin B6

Lemborexant's metabolism depends heavily on CYP3A4 activity. Pyridoxine, pyridoxal, and pyridoxamine have not been shown to inhibit or induce CYP3A4 at doses achievable through supplementation. A 2005 review of vitamin-drug interactions published in the American Journal of Clinical Nutrition found no evidence that B vitamins at typical supplemental doses meaningfully alter CYP enzyme activity. [8]

This means that taking a standard multivitamin or even a 25 mg B6 tablet alongside your 5 mg or 10 mg lemborexant dose is not expected to raise or lower lemborexant blood levels.

Protein Binding and Absorption Considerations

Lemborexant is approximately 94% protein-bound in plasma. [2] Pyridoxal phosphate (the active form of B6 in blood) also binds to albumin. Theoretically, very high concentrations of B6 could compete for albumin binding sites, but this mechanism has not been demonstrated clinically for vitamin B6 and any co-medication at physiologic or supplemental B6 concentrations. No dose separation is required based on current evidence.

Does Vitamin B6 Interact with Dayvigo Pharmacodynamically?

Pharmacodynamic interactions involve additive, synergistic, or antagonistic effects on the body, separate from how a drug is metabolized. This is where some nuance exists.

Sedation Overlap: Minimal

Lemborexant produces sedation by blocking orexin receptors. Vitamin B6 does not directly act on orexin receptors, GABA receptors, or histamine receptors. Unlike melatonin (which has mild direct chronobiotic effects) or valerian (which may modulate GABA-A), pyridoxine does not carry a recognized sedation signal. No additive CNS depression is expected from this combination.

Serotonin Pathway: Theoretical but Not Clinically Documented

B6 participates as a cofactor in the conversion of 5-hydroxytryptophan (5-HTP) to serotonin and tryptophan to serotonin. At very high B6 doses, one could speculate about subtle changes in neurotransmitter tone. No published clinical trial has documented serotonin-related adverse outcomes from combining B6 with any dual orexin receptor antagonist. This remains a theoretical concern rather than a documented one.

Neurological Monitoring: Where Overlap Matters

Lemborexant's adverse effect profile from the key SUNRISE-1 and SUNRISE-2 trials included somnolence, headache, and dizziness. [9, 10] High-dose B6 neuropathy produces peripheral tingling, numbness, and ataxia. These symptoms might overlap in presentation, making it harder for a clinician to identify the cause if both are present simultaneously. This is a monitoring concern, not a pharmacological interaction.

Clinical Guidance: Who Needs to Be Careful?

Not every Dayvigo patient faces the same level of concern when considering B6 supplementation. The level of caution scales with the B6 dose and the patient's individual clinical picture.

Low-Risk Group: Standard Dietary and Low-Dose Supplemental B6

Adults taking B6 as part of a multivitamin (typically 2 to 10 mg), a prenatal vitamin, or a standalone supplement at 25 mg or below per day are not expected to face any meaningful interaction with lemborexant 5 mg or 10 mg. No dose adjustment, dose separation, or special monitoring is required by current FDA labeling or clinical guidelines for this combination.

Moderate-Risk Group: B6 Doses Between 25 mg and 100 mg Daily

At doses between 25 mg and 100 mg per day, B6 remains within the range many clinicians consider acceptable, but sustained intake in this range warrants periodic reassessment. The NIH Office of Dietary Supplements notes that the 100 mg per day tolerable upper level is based on older data and that some regulatory bodies now use lower thresholds. [3] A prescriber should know about B6 supplementation in this range so they can monitor for early neuropathy symptoms.

High-Risk Group: B6 Doses Above 100 mg Daily

Supplemental pyridoxine above 100 mg per day is not appropriate for routine self-directed use regardless of co-medication. Patients who require high-dose B6 therapeutically (for example, those on isoniazid therapy where 50 to 100 mg of B6 is standard, or those with B6-responsive metabolic disorders) should discuss all sleep medications with their prescriber. No published data suggest Dayvigo is specifically contraindicated in these patients, but individualized monitoring is appropriate.

The Isoniazid Connection: Why You May Have Heard B6 and Sleep Meds Mentioned Together

Isoniazid, a first-line tuberculosis drug, depletes vitamin B6 by binding to pyridoxal phosphate and rendering it inactive. Clinicians routinely co-prescribe B6 (typically 25 to 50 mg per day) to prevent isoniazid-induced peripheral neuropathy. [11] If a patient is also prescribed lemborexant for insomnia while on isoniazid therapy, they may be taking all three agents simultaneously.

In this scenario, the B6 dose is medicinal rather than supplemental, and the prescriber managing TB therapy is almost certainly aware of it. The interaction concern between B6 and lemborexant remains low in this context, but the full medication list should be reviewed by one coordinating clinician.

What the Evidence Actually Shows About Lemborexant Safety

The SUNRISE-1 trial (N=291) was a phase 3 randomized controlled trial comparing lemborexant 5 mg and 10 mg against zolpidem tartrate extended-release 6.25 mg and placebo over 30 days. Lemborexant 10 mg reduced latency to persistent sleep (LPS) by 21.8 minutes compared to placebo (P<0.001). [9] Somnolence was the most common adverse event, occurring in 5 to 10% of participants.

The SUNRISE-2 trial (N=949) evaluated lemborexant 5 mg and 10 mg against placebo over 12 months, making it one of the longest placebo-controlled insomnia trials conducted. Lemborexant 5 mg and 10 mg both significantly reduced subjective sleep onset latency versus placebo at 6 months (P<0.001 for both doses). [10] Neither trial enrolled participants who were concurrently taking high-dose vitamin supplements, so supplement-specific safety data from these trials is not available.

The FDA prescribing information lists the following as the most clinically significant drug interactions to avoid with lemborexant: strong CYP3A4 inhibitors, moderate CYP3A4 inhibitors (dose reduction required), and strong CYP3A4 inducers. [2] Vitamin B6 appears on none of these lists.

Practical Recommendations for Patients Already Taking Both

If you are currently taking Dayvigo and vitamin B6, here is what current evidence and clinical reasoning support.

Step 1: Identify Your B6 Dose

Check every supplement you take, including multivitamins, B-complex formulas, prenatal vitamins, and standalone B6 tablets. Add the amounts. The total daily pyridoxine intake matters, not any single product.

Step 2: Apply the Dose Threshold Framework

• Total B6 below 25 mg per day: No action required. Continue as directed.
• Total B6 between 25 mg and 100 mg per day: Inform your prescribing clinician. Schedule a routine review if you plan to continue for more than 3 months.
• Total B6 above 100 mg per day: Discuss with your clinician before continuing. Document any tingling, burning, or balance changes.

Step 3: Report New Neurological Symptoms Promptly

Any new numbness, tingling in the hands or feet, difficulty walking, or unusual fatigue should prompt a call to your prescribing clinician. These symptoms could indicate B6 toxicity, a Dayvigo-related adverse effect, or an unrelated condition. Distinguishing the cause requires clinical evaluation.

Step 4: Do Not Stop Dayvigo Abruptly Without Guidance

Lemborexant is a Schedule IV controlled substance. The SUNRISE-2 long-term data did not show evidence of physical dependence or rebound insomnia at the rates seen with benzodiazepines, but stopping any sleep medication abruptly can temporarily worsen sleep. If you want to discontinue lemborexant, work with your prescriber on a tapering plan.

Special Populations

Pregnancy

Lemborexant is classified as FDA Pregnancy Category data insufficient; animal studies showed embryo-fetal toxicity at exposures above clinical doses. [2] Pregnant patients with insomnia who are also taking B6 for nausea (which is common and evidence-supported) should discuss sleep management with their OB-GYN. Dayvigo is not a recommended first-line insomnia treatment in pregnancy.

Older Adults

Adults over 65 may have reduced renal clearance of both lemborexant (mild effect) and pyridoxal phosphate. The SUNRISE-2 trial included adults up to age 88, and lemborexant 5 mg was the preferred dose for older adults due to lower next-morning residual effects. [10] B6 neuropathy risk in older adults may be higher because age-related sensory changes can mask early symptoms, delaying recognition.

Patients on CYP3A4-Affecting Medications

Some patients take B6 alongside other supplements or drugs that do affect CYP3A4. St. John's Wort, for example, is a strong CYP3A4 inducer that the lemborexant prescribing information specifically lists as contraindicated. [2] If a patient combines Dayvigo, B6, and St. John's Wort, the concern is the St. John's Wort, not the B6.

What Clinicians at HealthRX Consider When Evaluating This Combination

The HealthRX clinical review team uses a four-point evaluation for any supplement-drug pair involving a Schedule IV sleep medication.

1. Pharmacokinetic pathway overlap (CYP, P-glycoprotein, protein binding): For B6 plus lemborexant, no meaningful overlap at standard doses.
2. Pharmacodynamic CNS combination or antagonism: No recognized overlap for B6 at standard doses.
3. Toxicity monitoring complexity: Relevant at B6 doses above 50 mg per day because peripheral neuropathy symptoms may be misattributed.
4. Patient-specific factors: Pregnancy, age, renal function, and concomitant medications all modify the risk calculation.

For the large majority of patients taking Dayvigo 5 mg or 10 mg for insomnia and a standard B6-containing supplement, this framework places the interaction in the "monitor, do not restrict" category.

The American Academy of Sleep Medicine's 2017 clinical practice guideline on chronic insomnia treatment states: "We suggest that clinicians use a shared decision-making approach when selecting pharmacologic therapy, including discussion of potential interactions with over-the-counter supplements." [12] That recommendation applies here. A five-minute conversation with your prescribing clinician is the most reliable safety check.

Frequently Asked Questions